Pharmacophore and QSAR Modeling of Endothelial Nitric Oxide Synthase Inhibitors and Subsequent Validation and In Silico Search for New Hits

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Jordan Journal of Pharmaceutical Sciences

• Publication date

  2012-09-25

• Fields of study

  Medicine, Chemistry

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of new β-d-glucosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening

  2011cited by this paper
• Oxidative stress and endothelial function: therapeutic interventions.

  2011cited by this paper
• Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.

  2011cited by this paper
• Discovery of new β‐D‐galactosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening

  2011cited by this paper
• Pharmacophore and QSAR modeling of estrogen receptor beta ligands and subsequent validation and in silico search for new hits.

  2010cited by this paper
• Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.

  2010cited by this paper
• Targeting the L-arginine-nitric oxide pathway for cancer treatment.

  2010cited by this paper
• Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.

  2010cited by this paper
• Synthesis of N-(Methoxycarbonylthienylmethyl)thioureas and Evaluation of Their Interaction with Inducible and Neuronal Nitric Oxide Synthase

  2010cited by this paper
• Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability.

  2009cited by this paper
• Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping.

  2009cited by this paper
• Crystal structures of constitutive nitric oxide synthases in complex with de novo designed inhibitors.

  2009cited by this paper
• Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis, and Shape-Complemented in Silico Screening Allow Access to Novel Influenza Neuraminidase Inhibitors

  2009cited by this paper
• Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.

  2008cited by this paper
• Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.

  2008cited by this paper
• Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors.

  2008cited by this paper
• Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—What can we learn from earlier mistakes?

  2008cited by this paper
• Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.

  2008cited by this paper
• Discovery of DPP IV Inhibitors by Pharmacophore Modeling and QSAR Analysis followed by in silico Screening

  2008cited by this paper
• Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity

  2007cited by this paper
• An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer.

  2007cited by this paper
• Selective L-nitroargininylaminopyrrolidine and L-nitroargininylaminopiperidine neuronal nitric oxide synthase inhibitors.

  2007cited by this paper
• Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.

  2007cited by this paper
• Insights into ligand selectivity in nitric oxide synthase isoforms: a molecular dynamics study.

  2007cited by this paper
• Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors.

  2007cited by this paper
• Structure-based design and synthesis of N(omega)-nitro-L-arginine-containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water.

  2007cited by this paper
• Structural studies of constitutive nitric oxide synthases with diatomic ligands bound

  2006cited by this paper
• Conformationally restricted dipeptide amides as potent and selective neuronal nitric oxide synthase inhibitors.

  2006cited by this paper
• Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions.

  2006cited by this paper
• Hydroxyl-terminated peptidomimetic inhibitors of neuronal nitric oxide synthase.

  2006cited by this paper
• Virtual ligand screening: strategies, perspectives and limitations

  2006cited by this paper
• Exploring the binding conformations of bulkier dipeptide amide inhibitors in constitutive nitric oxide synthases.

  2005cited by this paper
• Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer

  2005cited by this paper
• Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer

  2005cited by this paper
• Virtual Screening Using Protein—Ligand Docking: Avoiding Artificial Enrichment.

  2004cited by this paper
• Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography.

  2004cited by this paper
• Structures of the neuronal and endothelial nitric oxide synthase heme domain with D-nitroarginine-containing dipeptide inhibitors bound.

  2004cited by this paper
• iNOS-mediated nitric oxide production and its regulation.

  2004cited by this paper
• Virtual Screening Using Protein-Ligand Docking: Avoiding Artificial Enrichment

  2004cited by this paper
• Aktan, F.: iNOS-mediated nitric oxide production and its regulation. Life Sci. 75, 639-653

  2004cited by this paper
• GPCRs: an update on structural approaches to drug discovery

  2003cited by this paper
• Nitric oxide: therapeutic opportunities

  2003cited by this paper
• Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors.

  2003cited by this paper
• Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase.

  2003cited by this paper
• The statistical sleuth : a course in methods of data analysis

  2002cited by this paper
• Molecular properties that influence the oral bioavailability of drug candidates.

  2002cited by this paper
• Current trends in QSAR on NO donors and inhibitors of nitric oxide synthase (NOS) * †

  2002cited by this paper
• pH‐Dependent Binding Modes Observed in Trypsin Crystals: Lessons for Structure‐Based Drug Design

  2002cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• A potent inhibitor of inducible nitric oxide synthase, ONO-1714, a cyclic amidine derivative.

  2000cited by this paper
• Nitric oxide synthase: models and mechanisms.

  2000cited by this paper
• Synthesis and evaluation of peptidomimetics as selective inhibitors and active site probes of nitric oxide synthases.

  2000cited by this paper
• 1H-pyrazole-1-carboxamidines: new inhibitors of nitric oxide synthase.

  2000cited by this paper
• Imidazole-containing amino acids as selective inhibitors of nitric oxide synthases.

  1999cited by this paper
• Specificity of inducible nitric-oxide synthase inhibitors: prospects for their clinical therapy.

  1999cited by this paper
• Nω-Nitroarginine-Containing Dipeptide Amides. Potent and Highly Selective Inhibitors of Neuronal Nitric Oxide Synthase

  1999cited by this paper
• Inducible nitric oxide synthase in human diseases

  1998cited by this paper
• Crystal structure of constitutive endothelial nitric oxide synthase: a paradigm for pterin function involving a novel metal center.

  1998cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

  1997cited by this paper
• International Union of Pharmacology Nomenclature in Nitric Oxide Research.

  1997cited by this paper
• Potent and selective inhibition of neuronal nitric oxide synthase by N omega-propyl-L-arginine.

  1997cited by this paper
• Potent and selective inhibition of neuronal nitric oxide synthase by N(ω)-propyl-L-arginine

  1997cited by this paper
• The structure of nitric oxide synthase oxygenase domain and inhibitor complexes.

  1997cited by this paper
• Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters.

  1997cited by this paper
• S-alkyl-L-thiocitrullines. Potent stereoselective inhibitors of nitric oxide synthase with strong pressor activity in vivo

  1995cited by this paper
• Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase.

  1995cited by this paper
• Nitric oxide: a physiologic messenger molecule.

  1994cited by this paper
• Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase.

  1989cited by this paper
• Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.

  1987cited by this paper
• Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

  1987cited by this paper
• The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine

  1980cited by this paper

• Discovery of promising FtsZ inhibitors by E-pharmacophore, 3D-QSAR, molecular docking study, and molecular dynamics simulation

  2019cites this paper
• Ritodrine inhibits neuronal nitric oxide synthase, a potential link between tocolysis and autism

  2014cites this paper